9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer
Abstract Glycogen synthase kinase-3 beta (GSK-3β), a serine/threonine kinase, has been identified as a potential therapeutic target in human bladder cancer. In the present study, we investigated the antitumor effect of a small molecule GSK-3β inhibitor, 9-ING-41, currently in clinical studies in pat...
Main Authors: | Hiroo Kuroki, Tsutomu Anraku, Akira Kazama, Vladimir Bilim, Masayuki Tasaki, Daniel Schmitt, Andrew P. Mazar, Francis J Giles, Andrey Ugolkov, Yoshihiko Tomita |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2019-12-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-019-56461-4 |
Similar Items
-
Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models
by: Andrey Ugolkov, et al.
Published: (2017-08-01) -
GSK-3β in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties
by: Robin Park, et al.
Published: (2021-07-01) -
Limited significance of repeated long-term radiological and hormonal examination in nonfunctioning adrenal incidentalomas
by: Masayuki Tasaki, et al. -
Congenital Scaphoid Megalourethra: A Case Report
by: Kenji Obara, et al.
Published: (2017-09-01) -
Bladder tissue pharmacokinetics of anticancer drugs /
by: Song, Di
Published: (1996)